Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  246.29
+4.73 (1.96%)
AAPL  259.04
-1.29 (-0.50%)
AMD  204.68
-5.34 (-2.54%)
BAC  56.18
+0.54 (0.97%)
GOOG  326.01
+3.58 (1.11%)
META  646.06
-2.63 (-0.41%)
MSFT  478.11
-5.36 (-1.11%)
NVDA  185.04
-4.07 (-2.15%)
ORCL  189.65
-3.19 (-1.65%)
TSLA  435.80
+4.39 (1.02%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.